PURPOSE OF REVIEW: The most common prostatic cancers (PCa) are acinary adenocarcinomas. Histological subtypes have been variably defined. The purpose of this review is to discuss unusual histological patterns and subtypes of acinar adenocarcinoma, as well as other types of PCa and their prognostic and therapeutic relevance. RECENT FINDINGS: The new term 'subtype' for morphologically defined tumor entities replaced the term 'variant' in the new 2022 classification of the WHO to allow for clear terminological distinction from genetic variants. The 2022 WHO classification mentions prostatic intraepithelial neoplasia (PIN)-like carcinoma, signet-cell-like adenocarcinoma, sarcomatoid carcinoma and pleomorphic-giant-cell adenocarcinoma of the prostate as true subtypes of acinary PCa. Other forms of acinary PCa are termed unusual histological patterns and include atrophic, foamy-cell, microcystic, pseudohyperplastic and mucinous patterns. Nonacinar forms of prostate cancer include other glandular PCa, the ductal adenocarcinoma and the treatment-associated neuroendocrine carcinoma, and nonglandular PCa, the adenosquamous carcinoma, the squamous cell carcinoma and the adenoid cystic (basal cell) carcinoma of the prostate. SUMMARY: True subtypes of acinary PCa and other forms of glandular and nonglandular PCa show relevant differences in prognosis and treatment approach compared with classic acinary PCa. The relevance of unusual histological patterns mainly lies in their deceptive benign appearance and the need for pathologists to know about these entities for accurate and timely diagnosis.

Department of Pathology General Hospital of Vienna

Department of Pathology Sorbonne University Assistance Publique Hôpital de Paris Hopital Tenon Paris France

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology University of Texas Southwestern Dallas Texas USA

Department of Urology Weill Cornell Medical College New York New York

Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan

Karl Landsteiner Society Vienna Austria

See more in PubMed

Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2022. CA Cancer J Clin 2022; 72:7–33.

WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. Lyon (France): International Agency for Research on Cancer; 2022.

Eble JN, Sauter G, Epstein J, et al. World Health Organization Classification for tumour. Pathology and genetics of tumours of the urinary system and male genital organs. 2004.

Humphrey PA. Variants of acinar adenocarcinoma of the prostate mimicking benign conditions. Mod Pathol 2018; 31 (S1):S64–S70.

Egan AJ, Lopez-Beltran A, Bostwick DG. Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. Am J Surg Pathol 1997; 21:931–935.

Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 1997; 49: (3A Suppl): 16–22.

Farinola MA, Epstein JI. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol 2004; 35:1272–1278.

Tan H-L, Haffner MC, Esopi DM, et al. Prostate adenocarcinomas aberrantly expressing P63 are molecularly distinct from usual-type prostatic adenocarcinomas. Mod Pathol 2015; 28:446–456.

Kaleem Z, Swanson PE, Vollmer RT, et al. Prostatic adenocarcinoma with atrophic features: a study of 202 consecutive completely embedded radical prostatectomy specimens. Am J Clin Pathol 1998; 109:695–703.

Humphrey PA, Kaleem Z, Swanson PE, et al. Pseudohyperplastic prostatic adenocarcinoma. Am J Surg Pathol 1998; 22:1239–1246.

Yaskiv O, Cao D, Humphrey PA. Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns. Am J Surg Pathol 2010; 34:556–561.

Hudson J, Cao D, Vollmer R, et al. Foamy gland adenocarcinoma of the prostate: incidence, Gleason grade, and early clinical outcome. Hum Pathol 2012; 43:974–979.

Osunkoya AO. Mucinous and secondary tumors of the prostate. Mod Pathol 2018; 31 (S1):S80–S95.

Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol 2016; 70:106–119.

Bronkema C, Arora S, Sood A, et al. Rare histological variants of prostate adenocarcinoma: a national cancer database analysis. J Urol 2020; 204:260–266.

Samaratunga H, Delahunt B, Srigley JR, et al. Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology 2017; 71:641–647.

Zhao F, Yu X, Xu M, et al. Mucinous prostate cancer shows similar prognosis to typical prostate acinar carcinoma: a large population-based and propensity score-matched study. Front Oncol 2019; 9:1467.

Hameed O, Humphrey PA. Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol 2006; 19:899–906.

Tavora F, Epstein JI. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases. Am J Surg Pathol 2008; 32:1060–1067.

Paulk A, Giannico G, Epstein JI. PIN-like (ductal) adenocarcinoma of the prostate. Am J Surg Pathol 2018; 42:1693–1700.

Ro JY, el-Naggar A, Ayala AG, et al. Signet-ring-cell carcinoma of the prostate. Electron-microscopic and immunohistochemical studies of eight cases. Am J Surg Pathol 1988; 12:453–460.

Park JJ, Snow ZA, Lurz KL, et al. A rare case of signet ring cell carcinoma of the colon with selective metastasis to the prostate. Urology 2020; 143:e17–e19.

Warner JN, Nakamura LY, Pacelli A, et al. Primary signet ring cell carcinoma of the prostate. Mayo Clin Proc 2010; 85:1130–1136.

Hansel DE, Epstein JI. Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am J Surg Pathol 2006; 30:1316–1321.

Huan Y, Idrees M, Gribetz ME, et al. Sarcomatoid carcinoma after radiation treatment of prostatic adenocarcinoma. Ann Diagn Pathol 2008; 12:142–145.

McKenney JK. Mesenchymal tumors of the prostate. Mod Pathol 2018; 31 (S1):S133–S142.

Rodrigues DN, Hazell S, Miranda S, et al. Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin. Histopathology 2015; 66:898–901.

Salvi S, Casadio V, Martignano F, et al. Carcinosarcoma of the prostate: case report with molecular and histological characterization. Int J Biol Markers 2018; 33:540–544.

Renshaw AA, Granter SR. Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration. Diagn Cytopathol 2000; 23:199–201.

Lopez-Beltran A, Eble JN, Bostwick DG. Pleomorphic giant cell carcinoma of the prostate. Arch Pathol Lab Med 2005; 129:683–685.

Alharbi AM, De Marzo AM, Hicks JL, et al. Prostatic adenocarcinoma with focal pleomorphic giant cell features: a series of 30 cases. Am J Surg Pathol 2018; 42:1286–1296.

Larnaudie L, Compérat E, Conort P, Varinot J. HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature. Virchows Arch 2017; 471:133–136.

Gillard M, Lack J, Pontier A, et al. Integrative genomic analysis of coincident cancer foci implicates CTNNB1 and PTEN alterations in ductal prostate cancer. Eur Urol Focus 2019; 5:433–442.

Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol 2009; 22:359–365.

Morais CL, Herawi M, Toubaji A, et al. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. Prostate 2015; 75:1610–1619.

Schweizer MT, Antonarakis ES, Bismar TA, et al. Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. JCO Precis Oncol 2019; 3:PO.18.00327.

Han B, Mehra R, Suleman K, et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 2009; 22:1176–1185.

Vinceneux A, Bruyère F, Haillot O, et al. Ductal adenocarcinoma of the prostate: clinical and biological profiles. Prostate 2017; 77:1242–1250.

Schweizer MT, Cheng HH, Tretiakova MS, et al. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget 2016; 7:82504–82510.

Umeda K, Kosaka T, Nakamura K, et al. A Japanese patient with ductal carcinoma of the prostate carrying an adenomatosis polyposis coli gene mutation: a case report. Diagn Pathol 2020; 15:102.

Sha J, Bo J, Pan J, et al. Ductal adenocarcinoma of the prostate: immunohistochemical findings and clinical significance. Onco Targets Ther 2013; 6:1501–1506.

Morgan TM, Welty CJ, Vakar-Lopez F, et al. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased PSA secretion. J Urol 2010; 184:2303–2307.

Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 1999; 23:1471–1479.

Ranasinghe W, Shapiro DD, Hwang H, et al. Ductal prostate cancers demonstrate poor outcomes with conventional therapies. Eur Urol 2021; 79:298–306.

Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol 2014; 32:3383–3390.

Metzger AL, Abel S, Wegner RE, et al. Patterns of care and outcomes in small cell carcinoma of the prostate: a national cancer database analysis. Prostate 2019; 79:1457–1461.

Conteduca V, Oromendia C, Eng KW, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer 2019; 121:7–18.

Park JW, Lee JK, Sheu KM, et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 2018; 362:91–95.

Zou M, Toivanen R, Mitrofanova A, et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov 2017; 7:736–749.

Mu P, Zhang Z, Benelli M, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 2017; 355:84–88.

Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1:487–495.

Wang J, Wang FW, Lagrange CA, et al. Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate. Rare Tumors 2010; 2:e47.

Kanthan R, Torkian B. Squamous cell carcinoma of the prostate. A report of 6 cases. Urol Int 2004; 72:28–31.

Iczkowski KA, Ferguson KL, Grier DD, et al. Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases. Am J Surg Pathol 2003; 27:1523–1529.

Alhamar M, Tudor Vladislav I, Smith SC, et al. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. Histopathology 2020; 77:890–899.

Dizman N, Salgia M, Ali SM, et al. Squamous transformation of prostate adenocarcinoma: a report of two cases with genomic profiling. Clin Genitourin Cancer 2020; 18:e289–e292.

Lara PN, Heilmann AM, Elvin JA, et al. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. JCO Precis Oncol 2017; 2017:PO.17.00065.

Simper NB, Jones CL, MacLennan GT, et al. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. Hum Pathol 2015; 46:805–812.

Magers MJ, Iczkowski KA, Montironi R, et al. MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. Mod Pathol 2019; 32:1666–1674.

Bishop JA, Yonescu R, Epstein JI, Westra WH. A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma. Hum Pathol 2015; 46:1204–1208.

Rebhan K, Wasinger G, Hassler MR, et al. Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review. Curr Opin Urol 2022; 32:358–363.

Grossman JE, Wu Y, Ye H, et al. Case of basal cell carcinoma of the prostate successfully treated before and after a BRCA2 reversion mutation. JCO Precis Oncol 2018; 2:PO.18.00193.